Understanding Your CML Treatment Response: BCR-ABL1 Kinase Domain Mutation Analysis
When you’re battling chronic myeloid leukaemia, discovering that your current treatment might not be working as effectively can be concerning and overwhelming. We understand that feeling of uncertainty when blood counts aren’t responding as expected, or when side effects seem disproportionate to the benefits. Our BCR-ABL1 Kinase Domain Mutation Analysis provides the clarity you need to understand why your treatment may be losing effectiveness and what genetic factors could be influencing your response.
What This Test Reveals About Your Treatment
This advanced genetic analysis specifically examines the BCR-ABL1 gene’s kinase domain – the area where tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib target CML cells. When mutations develop in this critical region, they can prevent these life-saving medications from working properly, leading to treatment resistance. Our test identifies these specific genetic changes, giving you and your oncologist valuable information to guide treatment adjustments.
When Should You Consider This Analysis?
This test becomes particularly important if you’re experiencing:
- Rising BCR-ABL1 transcript levels despite ongoing TKI therapy
- Failure to achieve expected molecular responses within treatment timelines
- Loss of previously achieved molecular response
- Progression from chronic phase to accelerated or blast phase CML
- Planning for treatment changes or considering alternative TKI options
Many South African patients find this analysis crucial when their current treatment approach needs re-evaluation, especially when managing CML long-term.
Why Early Detection of Mutations Matters for Your Health
Identifying treatment-resistant mutations early provides significant advantages:
- Timely Treatment Adjustments: Switch to alternative TKIs before resistance progresses
- Personalised Therapy: Choose medications based on your specific genetic profile
- Improved Outcomes: Maintain better disease control and quality of life
- Reduced Anxiety: Understand the reason behind treatment challenges
- Cost Efficiency: Avoid continuing ineffective treatments unnecessarily
Understanding Your Test Results
Your results will clearly indicate whether mutations are present in the BCR-ABL1 kinase domain and identify specific mutation types if detected. Our comprehensive report includes:
- Clear mutation status (detected/not detected)
- Specific mutation identification when present
- Interpretation of clinical significance
- Guidance on potential treatment implications
- Recommendations for discussion with your oncologist
We provide this information in accessible language, supported by our genetic counselling team if you need further explanation.
Transparent Pricing – Investing in Your Health Future
| Service | Regular Price | Special Price | Savings |
|---|---|---|---|
| BCR-ABL1 Kinase Domain Mutation Analysis | ZAR 6,700 | ZAR 5,000 | ZAR 1,700 |
Note: This test requires a doctor’s prescription and is not applicable for surgery, pregnancy cases, or travel abroad documentation.
Why Trust Oracle Genomics With Your Genetic Testing?
- Nationwide Coverage: Accessible testing centres in Johannesburg, Cape Town, Durban, Pretoria and across South Africa
- Advanced Technology: Next-generation sequencing (NGS) for unparalleled accuracy
- Expert Interpretation: Results analysed by experienced molecular pathologists
- Quick Turnaround: Results within 2-3 weeks to support timely treatment decisions
- Patient-Centred Approach: Empathetic support throughout your testing journey
Take Control of Your CML Management Today
Don’t let treatment uncertainty compromise your health journey. Early detection of resistance mutations can make a significant difference in your long-term CML management. Our team is ready to support you with accurate, reliable genetic analysis that empowers informed treatment decisions.
Act now while the special pricing of ZAR 5,000 is available. Understanding your genetic profile could be the key to more effective CML management and improved quality of life.
Sample Collection Information
Sample Type: Bone marrow or Peripheral blood (requires immediate transport)
Container: EDTA Vacutainer (2ml)
Method: Next-Generation Sequencing (NGS)
Turnaround Time: 2-3 weeks
